Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR228810 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose 1 IV infusion |
| Cohort 2 | EXPERIMENTAL | Dose 2 IV infusion |
| Cohort 3 | EXPERIMENTAL | Dose 3 IV infusion |
| Cohort 4 | EXPERIMENTAL | Dose 4 IV infusion |
| Cohort 5 | EXPERIMENTAL | Dose 1 SC injection |
| Cohort 6 | EXPERIMENTAL | Dose 2 SC injection |
| Name | Type | Description |
|---|---|---|
| SAR228810 | DRUG | Pharmaceutical form:solution Route of administration: intravenous |
Inclusion criteria: * Male or female patients with mild to moderate Alzheimer's disease, aged between 50 and 85 years inclusive * Meets criteria for probable Alzheimer's of the National Institute of Neurologic and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Associ...
Top 20 of 30 competitors
SAR228810 is an investigational small molecule developed by Sanofi for Alzheimer's disease. It was studied in a Phase 1 clinical trial evaluating single and repeated dosing in patients with Alzheimer's disease. The program is in early clinical development and is not approved for any indication.
SAR228810 was being developed as a treatment for Alzheimer's disease. A single Phase 1 trial enrolled 48 Alzheimer's patients to assess safety and the concentration-time profile of single and repeated doses. The study is completed, and the drug remains investigational rather than an approved therapy.
SAR228810 targets protofibrillar AB, a form of amyloid beta. The compound is described as a small molecule directed at this protofibrillar AB target. Targeting protofibrillar AB reflects an amyloid-directed approach to Alzheimer's disease, though the clinical program remained at the Phase 1 stage.
SAR228810 is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 1 study of the compound in Alzheimer's disease. The asset sits within Sanofi's neurology pipeline and has not advanced beyond early clinical testing.
SAR228810 is in Phase 1. One Phase 1 trial has been completed, and no active trials are ongoing. The study was randomized, double-blind, and controlled, enrolling 48 patients. SAR228810 is investigational and has not been approved by the FDA for Alzheimer's disease or any other indication.
SAR228810 was studied in trial NCT01485302, titled a single and repeated dosing study to assess safety and the concentration-time profile of SAR228810 in Alzheimer's patients. The Phase 1 trial enrolled 48 participants across Bulgaria, France, the Netherlands, South Africa, and Sweden, and it is completed.